explore -WSS

explore

author：comprehensive 2025-10-01 11:47:06 - browse：55791

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

WSS

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

FDA panel to weigh approval of NurOwn, controversial ALS drug

ASCO eve: Let’s set the table for this year's meeting

Biotech stock slump in 2023: awaiting the turnaround

Investigation reveals sickle cell patients pressured into sterilizations

It's been 20 years since Dolly the sheep. Where's my clone?

leisure time

explore

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Investigation reveals sickle cell patients pressured into sterilizations

Affirmative action in medical school literally saved lives

Biotech stock slump in 2023: awaiting the turnaround

George Santos makes 1st court appearance after pleading not guilty to 13 counts

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

ChatGPT in medicine: STAT answers readers' burning questions

Investigation reveals sickle cell patients pressured into sterilizations

Cancer drug shortages should be causing more outrage

Citing H5N1 threat, CDC urges peak flu monitoring this summer

knowledge

Addressing health care workers' trauma can help fight burnout

Liver decline slowed by off

Ukraine and a new approach to mental health in war

Intarcia’s device

Making the case for fair compensation in clinical trials

ASCO eve: Let’s set the table for this year's meeting

entertainment

leisure time

hotspot

explore